Healthcare

By

David Katz

 | Jul 27, 2016 | 7:00 AM EDT

It's too cheap for a biotech giant with years of patent protection for its key products and great cash flow.

By

Jim Cramer

 | Jul 26, 2016 | 8:15 AM EDT
One is rising on a minor sales bump while the other is falling despite solid results; and here is why.
By

Bruce Kamich

 | Jul 22, 2016 | 1:11 PM EDT
A shallow pullback in CNC should be viewed as a buying opportunity.
By

Bret Jensen

 | Jul 22, 2016 | 11:00 AM EDT
I expect Allergan or another player to bid for SGYP soon.
By

Bret Jensen

 | Jul 21, 2016 | 11:00 AM EDT
Watch these names as stability returns to the sector.
By

Bruce Kamich

 | Jul 18, 2016 | 12:05 PM EDT
Overall market and industry action could determine EW's next course.
By

Bret Jensen

 | Jul 18, 2016 | 11:00 AM EDT
The biotech juggernaut still has a lot going for it, especially at these levels.
By

David Katz

 | Jul 15, 2016 | 7:00 AM EDT
The drug maker is a compelling buy and has 50% upside potential over the next 18 to 24 months.
By

Bret Jensen

 | Jul 14, 2016 | 12:00 PM EDT
I still like and own these small-caps.
By

Jim Cramer

 | Jul 14, 2016 | 6:41 AM EDT
I say this to those who are angry.
Interface (TILE) posted 32-cents in its Q2 period versus a 28-cent consensus estimate.&nbs...
Markets in rally mode as Fed once again decides to leave rates unchanged in 9-1 vote. &nbs...
UPS will be reporting its 2nd quarter results before Friday's opening bell.  The stoc...
The FOMC essentially recycled the past couple of of policy statements at the conclusion of...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.